IDC-004

IDC-004 is a **preclinical discovery-stage angiogenesis inhibitor** reported in public company-pipeline context from **Prestige BioPharma**. Available public information identifies it as a program targeting **vascular endothelial growth factor A** and **zymogen granule protein 16 homolog B**, with the intended pharmacology of inhibiting pro-angiogenic signaling. No public source located in the provided context establishes a non-code generic name, brand name, specific molecular format, dosage form, route of administration, or a clearly disclosed disease indication beyond its positioning as an early oncology-oriented anti-angiogenic asset.